Table 1.
List of data collected at inclusion and follow-up visits.
| Inclusion visits | Follow-up visits | |
|---|---|---|
| Demographic characteristics | ||
| Age at inclusion | x | |
| Gender | x | |
| Relevant medical history | ||
| Comorbidities | x | |
| Auto-immune diseases | x | |
| Malignancies | x | |
| History of NMOSD | ||
| AQP4-IgG status | x | |
| MOG-IgG status | x | |
| Date of last relapse prior to inclusion | x | |
| Prior medication | x | |
| Evolution of NMOSD during follow-up | ||
| Relapse since last visit | x | |
| Type of relapse | x | |
| Acute therapies for relapse | x | |
| Hospitalization | x | |
| Recovery | x | |
| Clinical status | ||
| Ambulation | x | x |
| Functional scores (26) | x | x |
| EDSS (26) | x | x |
| 7.5-m walk test | x | x |
| NHP Test | x | x |
| Pain | x | x |
| Visual disability | x | x |
| Visual acuity in high and low contrast (Snellen test) | x | x |
| EQ-5D-5L | x | x |
| SF-36 | x | x |
| Brain and spine MRI | x | x |
| Use of eculizumab | ||
| Dosage and schedule of infusion | ||
| Antibioprophylaxis | x | x |
| Prophylaxis of Neisseria meningitis infections | x | |
| Discontinuation of eculizumab | x | |
| Use of concomitant therapies | x | |
| Concomitant therapies | x | x |
| Pain medications | x | x |
| Safety data | ||
| Any adverse events | x | |
| Serious adverse events | x | |
| Adverse events related to eculizumab | x | |
| Adverse events of special interest | x | |